With Sophy®, the 1st adjustable valve, and Polaris®, the 1st MRI-stable adjustable valve, Sophysa is the largest European shunt manufacturer for hydrocephalus treatment. With its great experience in the development of micro-mechanisms and implantable materials, Sophysa markets technically advanced solutions to serve the needs of healthcare providers and patients in three areas: Neurosurgery, Intensive Care Unit and Chemotherapy.
Founded in 1976, SOPHYSA was the pioneer in the development of adjustable neurosurgical valves to treat hydrocephalus. Introduced in 1984, the Sophy® valve was the first adjustable valve in the World allowing non-invasive adjustment of operating pressures, to match an individual patient’s changing clinical needs.
Sophysa’s core competency is the management of Cerebro-Spinal Fluid, allowing her to offer a platform of products for two major medical specialties, Neurosurgery and Neurotrauma.
In France and Benelux, Sophysa products are marketed by direct sales representatives. In the Rest of the World, Sophysa markets its products through an international network of exclusive distributors.